Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Pediatrics Faculty Publications

Pediatrics

9-2015

Discordant identification of pediatric severe sepsis
by research and clinical definitions in the SPROUT
international point prevalence study
S. L. Weiss
J. C. Fitzgerald
F. A. Maffei
J. M. Kane
A. Rodriguez-Nunez
See next page for additional authors

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs
Part of the Pediatrics Commons
Recommended Citation
Weiss, S. L., Fitzgerald, J. C., Maffei, F. A., Kane, J. M., Rodriguez-Nunez, A., Hsing, D. D., . . . Green, R. (2015). Discordant
identification of pediatric severe sepsis by research and clinical definitions in the SPROUT international point prevalence study.
Critical Care, 19(1) doi:10.1186/s13054-015-1055-x

This Journal Article is brought to you for free and open access by the Pediatrics at Health Sciences Research Commons. It has been accepted for
inclusion in Pediatrics Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.

Authors

S. L. Weiss, J. C. Fitzgerald, F. A. Maffei, J. M. Kane, A. Rodriguez-Nunez, Michael C. Spaeder, and +260
additional authors

This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs/1350

Weiss et al. Critical Care (2015) 19:325
DOI 10.1186/s13054-015-1055-x

RESEARCH

Open Access

Discordant identification of pediatric severe
sepsis by research and clinical definitions in the
SPROUT international point prevalence study
Scott L. Weiss1*, Julie C. Fitzgerald1, Frank A. Maffei2, Jason M. Kane3, Antonio Rodriguez-Nunez4, Deyin D. Hsing5,
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SPROUT Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network

Abstract
Introduction: Consensus criteria for pediatric severe sepsis have standardized enrollment for research studies.
However, the extent to which critically ill children identified by consensus criteria reflect physician diagnosis of
severe sepsis, which underlies external validity for pediatric sepsis research, is not known. We sought to determine
the agreement between physician diagnosis and consensus criteria to identify pediatric patients with severe sepsis
across a network of international pediatric intensive care units (PICUs).
Methods: We conducted a point prevalence study involving 128 PICUs in 26 countries across 6 continents. Over
the course of 5 study days, 6925 PICU patients <18 years of age were screened, and 706 with severe sepsis defined
either by physician diagnosis or on the basis of 2005 International Pediatric Sepsis Consensus Conference consensus
criteria were enrolled. The primary endpoint was agreement of pediatric severe sepsis between physician diagnosis
and consensus criteria as measured using Cohen’s κ. Secondary endpoints included characteristics and clinical
outcomes for patients identified using physician diagnosis versus consensus criteria.
Results: Of the 706 patients, 301 (42.6 %) met both definitions. The inter-rater agreement (κ ± SE) between physician
diagnosis and consensus criteria was 0.57 ± 0.02. Of the 438 patients with a physician’s diagnosis of severe sepsis, only
69 % (301 of 438) would have been eligible to participate in a clinical trial of pediatric severe sepsis that enrolled
patients based on consensus criteria. Patients with physician-diagnosed severe sepsis who did not meet consensus
criteria were younger and had lower severity of illness and lower PICU mortality than those meeting consensus criteria
or both definitions. After controlling for age, severity of illness, number of comorbid conditions, and treatment in
developed versus resource-limited regions, patients identified with severe sepsis by physician diagnosis alone or by
consensus criteria alone did not have PICU mortality significantly different from that of patients identified by both
physician diagnosis and consensus criteria.
Conclusions: Physician diagnosis of pediatric severe sepsis achieved only moderate agreement with consensus criteria,
with physicians diagnosing severe sepsis more broadly. Consequently, the results of a research study based on
consensus criteria may have limited generalizability to nearly one-third of PICU patients diagnosed with severe sepsis.
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Introduction
Sepsis is a leading cause of death in children worldwide,
responsible for an estimated 75,000 hospitalizations annually in the United States and nearly 50 % of all childhood
hospital deaths worldwide [1–5]. Within the spectrum of
this syndrome, severe sepsis refers to children with shock
or other organ dysfunction and is the high-risk group targeted for interventional studies in the pediatric intensive
care unit (PICU) [6].
Investigators in clinical trials of severe sepsis face important challenges that have contributed to high failure
rates for many promising novel therapies, with few attempts to include children [7]. One fundamental issue is
that the sepsis syndrome is characterized by non-specific
physiologic abnormalities that encompass a heterogeneous population. Consensus criteria for pediatric sepsis
were therefore established to facilitate consistent enrollment across research studies [6]. Many of these criteria
have since been adopted for use in clinical practice [8];
however, published reports have demonstrated only moderate overlap of physician diagnosis of severe sepsis with
consensus criteria [9, 10]. These findings raise concern
that many children diagnosed and treated for severe sepsis
in clinical practice may have important physiologic—and
outcome—differences from those studied in interventional
trials [9, 10].
The degree to which a study population is representative of patients diagnosed and treated in clinical practice
has a major impact on the external validity of a study
[11–13]. Although physician diagnosis serves clinical
practice and consensus criteria were intended primarily
for research, the alignment of these two methods to
identify children with severe sepsis will significantly impact the extent to which study results translate into
effective care at the bedside. Moreover, criteria that purposely define a disorder as a decompensated state at one
extreme of the entire spectrum—as the existing pediatric
consensus definitions currently do for severe sepsis and
septic shock—may hinder early clinical diagnosis or
delay enrollment in a clinical trial. Although the inherent challenge between research efficacy and clinical
effectiveness is not limited to sepsis [14–17], understanding the extent to which consensus criteria for
pediatric severe sepsis are in agreement with clinical
practice will help to improve understanding of the utility
of these criteria and to identify ways to improve both
physician diagnosis and consensus definitions. To date,
the agreement of physician diagnosis with consensus criteria for pediatric severe sepsis has not been evaluated in
a large-scale setting.
The Sepsis PRevalence, OUtcomes, and Therapies
(SPROUT) study researchers screened nearly 7000 PICU
patients for severe sepsis at 128 sites across 26 countries
using consensus criteria [18]. In addition, the attending
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physician caring for each patient provided an independent diagnostic assessment for severe sepsis. Using these
data, we determined the level of agreement between
consensus criteria [6] and attending physician diagnostic
assessment (“physician diagnosis”) for pediatric severe
sepsis. We hypothesized that agreement would be moderate at best, and thus we aimed to compare differences
in patient characteristics, treatment strategies, and outcomes for children identified as having severe sepsis by
consensus criteria versus physician diagnosis.

Material and methods
Study design

SPROUT was a prospective point prevalence study performed at 128 PICUs in 26 countries over the course of
5 study days spaced over 1 year [18]. Sites were recruited
by open invitation through established research networks, and participation was voluntary. Ethical approval
was obtained at all sites, and waiver of informed consent
was granted at all but three sites, at which written consent
was required for data collection (see Additional file 1 for a
list of all approving ethical bodies). The details of the
SPROUT study methodology have been published previously [18].
Study population

All patients <18 years of age being treated in a participating PICU at 9:00 AM local time on each study day
were screened for severe sepsis using a standardized
form incorporating the 2005 International Pediatric
Sepsis Consensus Conference criteria: (1) at least two
systemic inflammatory response syndrome criteria; (2)
confirmed or suspected invasive infection; and (3) cardiovascular dysfunction, acute respiratory distress syndrome (ARDS), or at least two organ dysfunctions [6].
The subset of patients with septic shock defined by cardiovascular dysfunction were included within the
spectrum of severe sepsis. Only data available within the
24 h preceding the 9:00 AM study day time were considered for screening, yielding a study cohort with active
severe sepsis. Patients who were ≥18 years of age, corrected gestational age <42 weeks, or had surgery involving cardiopulmonary bypass in the preceding 5 days
were excluded.
To ascertain physician diagnosis of severe sepsis, an
investigator at each site provided a list of patients, using
a standardized form, to the attending physician of record
on each study day. Attending physicians were instructed
as follows: “In your clinical opinion, does this patient
(yes or no) meet criteria for severe sepsis and/or septic
shock when considering data only from the past 24 h
(i.e., 9:00 AM yesterday to 9:00 AM today)?” Attending
physicians who provided diagnoses were not involved
with screening of patients for severe sepsis by consensus
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criteria. Similarly, site investigators screening for consensus criteria were blinded to physician diagnosis.
Data collection

Data were collected about demographics, comorbid conditions, admission source, laboratory results, and therapies
within a 48-h window around the study day (9:00 AM before to 9:00 AM after the study day). Definitions for the
primary site of infection were adapted from published criteria [18]. The day of severe sepsis recognition was identified as the first calendar day on which a patient met
consensus conference criteria for severe sepsis [6], and the
presence of new or progressive multiorgan dysfunction
syndrome (NPMODS) was measured for 7 days following
severe sepsis recognition [19–21]. New MODS was defined as no or one organ dysfunction at sepsis recognition
with subsequent development of at least two organ dysfunctions. Progressive MODS was defined as existing multiorgan dysfunction syndrome (MODS) (at least two
organ dysfunctions) at sepsis recognition with development of at least one other concurrent organ dysfunction.
For severe sepsis screening, organ dysfunctions were defined using pediatric sepsis consensus conference criteria
[6], whereas more stringent criteria were used to define
NPMODS [21]. For severity of illness, the Pediatric Index
of Mortality (PIM)-3 score [22] was calculated at PICU
admission, whereas the Pediatric Logistic Organ Dysfunction (PELOD) score [23] was calculated on the study day.
Patients with severe sepsis were followed for 90 days
or until death or hospital discharge. Outcomes included
vasoactive- and ventilator-free days from day of severe
sepsis recognition through day 28, NPMODS, change in
functional status from admission to hospital discharge
(using the Pediatric Overall Performance Category [POPC]
1–6 ordinal scale [24]), and all-cause mortality at PICU
discharge. Patients surviving to hospital discharge were
classified as having “at least mild disability” for any increase in POPC and “at least moderate disability” if discharge POPC was 3 or higher and increased by at least 1
from baseline [25].
All data were recorded and managed using standardized case report forms within the web-based Research
Electronic Data Capture (or REDCap) system, a secure
database that provides an intuitive interface for validated
data entry and audit trails for tracking data [26]. The
methods used to ensure data quality and confidentiality
have been published previously [18].
The primary outcome was the level of agreement in
identification of pediatric severe sepsis between physician diagnosis and consensus criteria. Secondary outcomes included differences in patient characteristics,
therapies used, and clinical outcomes between patients
identified using physician diagnosis versus consensus
criteria.
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Statistical analysis

Analyses were performed using STATA software (version
12.1; College Station, TX, USA). Data are presented as
medians with interquartile ranges for continuous variables and frequencies with percentages for categorical
variables. Comparisons between groups were performed
using the Kruskal-Wallis test for continuous variables,
and categorical variables were compared using Fisher’s
exact test. For variables in which significant differences
were identified across all three groups, pairwise comparisons were performed using Wilcoxon rank-sum or Fisher’s
exact tests for continuous or categorical variables, respectively. The level of agreement between the two methods to
identify patients with severe sepsis was quantified using
percentage agreement and Cohen’s κ. Multivariable logistic regression was used to test the independent association
of each definition of severe sepsis with PICU mortality
after controlling for patient-level variables found to be significantly different across groups. Status as a developed
(North America, Australia/New Zealand, and Europe) or
resource-limited (Asia, Africa, and South America) region
did not provide significant effect modification when
tested as an interaction term with definition of severe
sepsis (p = 0.36), but it was included as a confounder
in the final logistic regression model. Statistical significance was defined as a p value <0.05.

Results
Over the 5 study days, 6925 PICU patients were screened
across all sites. In total, 706 were identified with severe
sepsis by either consensus criteria or physician diagnosis,
with 137 patients (19.4 %) identified by physician diagnosis only, 301 (42.6 %) by both definitions, and 268 (38.0 %)
by consensus criteria only (Fig. 1). The percentage agreement between consensus criteria and physician diagnosis
for identifying severe sepsis in the entire cohort of
screened patients was 94 %, but it was only 43 % for identifying severe sepsis among the 706 patients with sepsis by
either definition. The inter-rater agreement between physician diagnosis and consensus criteria achieved a moderate
κ ± standard error of 0.57 ± 0.02. The percentage agreement between physician diagnosis and consensus criteria
varied significantly across geographic regions (p < 0.001).
Agreement was lowest in North America (31 % agreement
of 444 patients identified with severe sepsis by any criteria); moderate in Australia and New Zealand (45 %) and
Europe (51 %); and highest in Asia (72 %), Africa (72 %),
and South America (85 %). The percentage agreement
was 44 %, 49 %, 45 %, 38 %, and 39 % across study days 1–
5, respectively, suggesting that clinicians did not alter their
diagnostic assessment to better comply with consensus
criteria over time.
Of the 438 total patients with a physician diagnosis of
severe sepsis, 31 % were not concurrently identified with
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Fig. 1 Venn diagram of the overlap between patients identified with
severe sepsis by attending physician diagnostic assessment (“physician
diagnosis”) and the 2005 International Pediatric Sepsis Consensus
Conference (“consensus criteria”). Of the 6925 pediatric intensive care
unit patients screened, 706 were identified with severe sepsis but only
301 (43 %) were concurrently identified by both physician diagnosis
and consensus criteria (κ 0.57 ± 0.02)

severe sepsis by consensus criteria and thus would
have been ineligible to participate in a clinical trial
that enrolled patients based on the criteria established
by consensus guidelines. Moreover, 47 % of the patients identified as having severe sepsis by consensus
criteria—and thus potentially eligible for a clinical
trial—were not simultaneously considered to have severe sepsis by physician diagnosis.
Characteristics of 704 of the patients identified with
severe sepsis by physician diagnosis alone, by both definitions, or by consensus criteria alone are shown in
Table 1. Data could not be obtained for two patients
(both identified by consensus criteria alone) who did not
consent to data collection at one site that required informed consent for this purpose. Patients identified only
by physician diagnosis were younger (p = 0.008), had a
lower severity of illness (lower PIM-3 [p < 0.001] and
PELOD [p < 0.001] scores), and a lower proportion of
cardiovascular (p = 0.006) and hematologic dysfunction
(p < 0.001) at sepsis recognition than patients identified
by consensus criteria alone or both definitions. Patients
identified by consensus criteria alone were less likely to
be previously healthy (p = 0.002) and more likely to have
neuromuscular comorbidities (p < 0.001) than patients
identified by physician diagnosis alone or both definitions. Patients identified by consensus criteria alone
were more likely to have respiratory (p = 0.004) or unknown primary site of infection (p = 0.002) and less
likely to have primary bloodstream infection (p < 0.001).
Patients identified concurrently by both physician
diagnosis and consensus criteria had lower platelet
counts and higher blood lactate, C-reactive protein, and
procalcitonin levels than patients identified by either
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criterion alone (all p < 0.01) (Table 2). Similarly, patients
identified by both physician diagnosis and consensus criteria were also more likely to be treated with vasoactive
infusions, albumin, blood products, granulocyte/granulocyte macrophage colony-stimulating factor, intravenous
immunoglobulin, and renal replacement therapy than
patients identified by either criterion alone (all p < 0.05)
(Table 3).
PICU mortality was significantly lower for patients
with only a physician diagnosis of severe sepsis (18 %)
than with both definitions (27 %; p = 0.02) and trended
lower than for consensus criteria alone (21 %; p = 0.29;
Table 4). The proportion with NPMODS, at least mild
disability, and at least moderate disability all trended
lower for patients identified with severe sepsis by physician diagnosis alone, but none reached statistical significance. After controlling for age, PIM-3 score, number of
comorbid conditions, and treatment in developed versus
resource-limited regions, patients identified with severe
sepsis by physician diagnosis only or by consensus criteria only did not have PICU mortality different from
that of patients identified by both physician diagnosis
and consensus criteria (Table 5).

Discussion
Across this large international network of PICUs, physician diagnosis and consensus criteria achieved only a
moderate level of agreement in identifying critically ill
children with severe sepsis. These findings suggest that
the results of a research study with enrollment based only
on current consensus criteria may not be generalizable to
nearly one-third of pediatric patients diagnosed with severe sepsis in a PICU. Moreover, for nearly half of the patients identified with severe sepsis by consensus criteria,
and thus eligible for clinical trials, a diagnosis of severe
sepsis was not corroborated by the treating attending
physician.
The data in this study demonstrate that PICU physicians worldwide commonly diagnose critically ill children with severe sepsis who do not meet consensus
criteria. This finding is consistent with a prior report of
a single-center study in the United States [10]. In general, patients with physician-diagnosed severe sepsis
tended to be younger, less severely ill, and less likely to
receive several sepsis-related therapies than patients who
also met consensus criteria. These observations likely reflect the intention of the International Pediatric Sepsis
Consensus Conference to identify a more severely ill
subgroup of critically ill children with severe sepsis for
enrollment in clinical trials [6]. It may therefore be appropriate for physicians to diagnose severe sepsis more
often than consensus criteria, particularly in children
with a lower severity of illness who may need fewer adjunctive sepsis-related therapies. Physicians may also
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Table 1 Characteristics of patients identified with severe sepsis by physician diagnosis, consensus criteria, or both
Characteristic

Physician diagnosis

N

137

Age (yr)

1 (0.5–7)

Both criteria
301
3 (0.7–10)

Consensus criteria

p value*

266
3 (0.7–11)

Sex, n (%)

0.03
0.74

Male

76 (55)

164 (55)

138 (52)

Female

61 (45)

137 (45)

128 (48)

Respiratory

54 (39)

73 (24)

99 (37)

0.001

Gastrointestinal

40 (29)

62 (21)

79 (30)

0.03

Cardiovascular

34 (25)

62 (21)

74 (28)

0.13

Genetic

35 (26)

54 (18)

61 (23)

0.14

Hematologic/immunologic

28 (20)

69 (23)

45 (17)

0.21

Comorbid conditions, n (%)

Neuromuscular

11 (8)

37 (12)

60 (23)

<0.001

Neoplastic

18 (13)

51 (17)

29 (11)

0.11

Prematurity

37 (12)

24 (18)

39 (15)

0.35

Metabolic

17 (12)

28 (9)

34 (13)

0.38

Renal

15 (11)

24 (8)

31 (12)

0.31

8 (6)

28 (9)

26 (10)

0.39

30 (22)

85 (28)

43 (16)

Solid organ/stem cell transplant
Comorbid conditions, n (%)
None

<0.001

1

21 (15)

77 (26)

64 (24)

≥2

86 (63)

21 (15)

159 (60)

Good performance

70 (51)

170 (56)

120 (45)

Mild disability

26 (19)

44 (15)

41 (15)

Moderate disability

22 (16)

44 (15)

46 (17)

Admission POPC, n (%)

0.13

Severe disability or coma
PIM-3 scorea
b

PELOD score

19 (14)

43 (14)

59 (22)

3.6 (1.4–5.5)

4.4 (1.9–9.2)

4.3 (1.8–9.9)

<0.001

10 (1–11)

11 (2–13)

11 (2–12)

<0.001

Source of admission, n (%)
c

0.86

Emergency department

41 (30)

89 (30)

78 (29)

Hospital floor

39 (29)

92 (31)

66 (25)

Operating room

12 (9)

28 (9)

22 (8)

Other hospitald

39 (28)

77 (26)

89 (33)

Cardiovascular

51 (37)

182 (61)

106 (40)

<0.001

Respiratory

Organ dysfunction at sepsis recognitione

88 (64)

211 (70)

197 (74)

0.12

Renal

5 (4)

19 (6)

7 (3)

0.10

Hepatic

2 (1)

16 (5)

6 (2)

0.07

Hematologic

4 (3)

49 (16)

24 (9)

<0.001

Neurologic

9 (7)

28 (9)

33 (12)

0.17

Respiratory

60 (44)

101 (34)

127 (48)

0.002

Primary bloodstream

25 (18)

82 (27)

26 (10)

<0.001

Abdominal

15 (11)

31 (10)

16 (6)

0.11

Primary site of infection, n (%)

Weiss et al. Critical Care (2015) 19:325

Page 6 of 10

Table 1 Characteristics of patients identified with severe sepsis by physician diagnosis, consensus criteria, or both (Continued)
Central nervous system

3 (2)

9 (3)

16 (6)

0.11

Genitourinary

7 (5)

12 (4)

9 (3)

0.67

Skin

4 (3)

16 (5)

4 (2)

0.04

Other

6 (4)

16 (5)

13 (5)

0.95

17 (12)

34 (11)

55 (21)

0.006

Unknown
Microbiology,f,g n (%)
Gram-positive bacteria

39 (28)

90 (30)

60 (23)

0.13

Gram-negative bacteria

27 (20)

95 (32)

63 (24)

0.02

Fungus

9 (7)

39 (13)

37 (14)

0.07

Virus

35 (26)

50 (17)

69 (26)

0.01

No organism identified

50 (36)

95 (32)

101 (38)

0.25

Data are presented as median (IQR) unless otherwise noted
POPC Pediatric Overall Performance Category, ScvO2 central venous oxygen saturation, PIM-3 Pediatric Index of Mortality-3, PELOD Pediatric Logistic Organ Dysfunction,
PICU pediatric intensive care unit
*Statistical comparisons using Kruskal-Wallis or Fisher’s exact test
a
PIM-3 measured at time of PICU admission
b
PELOD score calculated from data within a 48-h time window around the study day (9:00 AM before to 9:00 AM after the study day)
c
Emergency department at the same hospital as the PICU
d
Other hospital includes emergency department at another hospital
e
Based on organ dysfunction criteria defined by the International Pediatric Sepsis Consensus Conference [6]
f
Categories do not add up to 100 %, as some infections were polymicrobial
g
Sources of positive isolates included blood, urine, cerebrospinal fluid, respiratory (nasopharynx, tracheal, bronchoalveolar lavage), stool, wound, and other
normally sterile body fluids (pleural, pericardial, peritoneal)

have been recognizing and treating children with sepsis
earlier in their illness course, at a point when they may
not yet have manifested the physiologic and laboratory
derangements required by consensus criteria. The loss of
a statistical difference in PICU mortality between patients identified by physician diagnosis alone and those
identified by both definitions after correcting for severity

of illness is consistent with these suppositions. A lower
threshold for diagnosing severe sepsis in clinical practice
likely accounts for the generally better outcome metrics
identified in epidemiologic studies using administrative
databases [1, 2, 5] than has been reported in clinical trials
[20, 27-29]. Our study therefore suggests caution when
extrapolating results from epidemiologic, observational,

Table 2 Laboratory values within the 48-h data collection window by definition of severe sepsis
Laboratory examination

Physician diagnosis
a

Both criteria
a

Consensus criteria
a

p value*

Percent

Median (IQR)

Percent

Median (IQR)

Percent

Median (IQR)

WBC, max (103/μl)

92 %

10.1 (7.3–16.6)

97 %

14.9 (7.5–22.7)

91 %

14.6 (8.8–20.8)

<0.001

Platelets, min (103/μl)

91 %

148 (70–262)

96 %

95 (39–195)

89 %

157 (77–287)

<0.001

BUN, max (mg/dl)

83 %

13 (8–22)

93 %

21 (12–41)

92 %

18 (10–31)

<0.001

Creatinine, max (mg/dl)

92 %

0.4 (0.3–0.6)

97 %

0.5 (0.3–0.9)

97 %

0.4 (0.3–0.7)

<0.001

ALT, max (IU/L)

55 %

39 (25–67)

77 %

53 (28–123)

62 %

50 (26–110)

0.09

Total bilirubin, max (mg/dl)

53 %

0.7 (0.4–1.7)

73 %

1.0 (0.5–2.9)

59 %

0.7 (0.4–3.0)

0.02

Albumin, min (g/dl)

66 %

2.6 (2.2–3.0)

81 %

2.5 (2.2–3.0)

71 %

2.8 (2.3–3.3)

<0.001

INR, max

37 %

1.3 (1.2–1.7)

64 %

1.3 (1.2–1.8)

42 %

1.3 (1.1–1.8)

0.80

Lactate, max (mmol/L)

62 %

1.4 (1.1–2.0)

75 %

2.0 (1.2–3.8)

62 %

1.6 (1.1–2.8)

0.001

ScvO2, min (%)

28 %

70 (57–75)

46 %

65 (52–74)

30 %

65 (49–73)

0.50

138 (89–233)

PaO2/FiO2 ratio, min (mmHg)

47 %

72 %

160 (100–236)

51 %

144 (87–275)

0.79

C-reactive peptide, max (mg/dl)

39 %

7.1 (2.1–17.8)

64 %

9.3 (2.8–20.8)

43 %

3.8 (1.6–9.7)

<0.001

Procalcitonin, max (ng/ml)

12 %

3.5 (1.1–11.6)

22 %

6.4 (1.4–23.0)

6%

1.3 (0.24–5.4)

0.01

max maximum value within the 48-h window around the study day (9:00 AM before to 9:00 AM after the study day), min minimum value within the 48-h window
around the study day (9:00 AM before to 9:00 AM after the study day), PaO2/FiO2 ratio of partial pressure of oxygen to fraction of inspired oxygen, WBC white
blood cell count, BUN blood urea nitrogen, ALT alanine aminotransferase, INR international normalized ratio, ScvO2 central venous oxygen saturation
*Statistical comparisons using Kruskal-Wallis test
a
Proportion of each group with available laboratory results

Weiss et al. Critical Care (2015) 19:325

Page 7 of 10

Table 3 Therapies used within the 48-h data collection window
by definition of severe sepsis

Table 5 Multivariable logistic regression model of the association
of severe sepsis definition with PICU mortality

Therapy

Variable

Adjusted ORa

Physician
diagnosis

Both
criteria

Consensus
criteria

p value*

Vasoactive infusionsa

53 (39)

209 (69)

105 (39)

<0.001

Invasive mechanical
ventilation

92 (67)

229 (76)

192 (72)

0.14

Corticosteroids

46 (36)

132 (44)

110 (41)

0.13

Albumin

24 (18)

90 (30)

45 (17)

<0.001

Blood productsb

39 (28)

159 (53)

73 (27)

<0.001

Insulin

4 (3)

32 (11)

25 (9)

0.02

G/GM-CSF

2 (1)

17 (6)

6 (2)

0.04

IVIG

7 (5)

28 (9)

10 (4)

0.02

RRTd

13 (9)

57 (19)

24 (9)

0.001

Plasma exchange

1 (1)

3 (1)

2 (1)

0.94

Developed regionb

ECMO

3 (2)

14 (5)

16 (6)

0.23

OR odds ratio, PIM-3 Pediatric Index of Mortality-3
a
Odds ratios are adjusted for all of the variables listed
b
Sites included as “developed regions” were located in North America,
Australia/New Zealand, and Europe

c

Data presented as n (%)
G/GM-CSF granulocyte/granulocyte-monocyte colony stimulating factor,
IVIG intravenous immunoglobulin, RRT renal replacement therapy,
ECMO extracorporeal membrane oxygenation
*Statistical comparisons using Fisher’s exact test
a
Includes dopamine >5 μg/kg/min, dobutamine >5 μg/kg/min, or any dose of
epinephrine, norepinephrine, vasopressin, phenylephrine, milrinone,
levosimendan, or vasodilator
b
Includes packed red blood cells, platelets, fresh frozen plasma,
cryoprecipitate, granulocytes, and whole blood
c
Includes intravenous insulin by continuous infusion only
d
Includes hemodialysis, all continuous renal replacement modalities, and
peritoneal dialysis

and interventional studies to this less severely ill subgroup
of patients who are diagnosed on the basis of physician
impression and do not meet consensus criteria. Conversely, the absence of certain features, such as two or
more systemic inflammatory response syndrome criteria
[30, 31], hypotension only after 40 ml/kg of intravenous
Table 4 Clinical outcomes by definition of severe sepsis
Outcome

Physician
diagnosis

Vasoactive-free days,
median (IQR)

27 (22–28)

Ventilator-free days,
median (IQR)

19 (2–27)

Both
criteria

Consensus
criteria

p value*

22 (6–26)

26 (17–28)

<0.001

16 (0–24)

18 (0–26)

0.07

NPMODSa

47 (34)

131 (44)

97 (36)

0.10

PICU mortality

23 (17)

82 (27)

57 (21)

0.042

At least mild disabilityb

24 (22)

67 (31)

50 (24)

0.15

At least moderate
disabilityc

14 (13)

36 (17)

37 (18)

0.46

Data presented as n (%) unless otherwise noted
IQR interquartile range, NPMODS new or progressive multiorgan dysfunction
syndrome, PICU pediatric intensive care unit
*Statistical comparisons using Kruskal-Wallis or Fisher’s exact test
a
NPMODS considered starting the day after sepsis recognition
b
Any increase in Pediatric Overall Performance Category from baseline to
hospital discharge in the 534 hospital survivors
c
Discharge Pediatric Overall Performance Category ≥3 and an increase of at
least 1 from baseline in the 534 hospital survivors

95 % confidence
interval

p value

Severe sepsis definition
Both criteria

Reference

Physician diagnosis, only

0.64

Consensus criteria, only

0.37–1.11

0.12

0.73

0.48–1.12

0.15

Age, yr

0.99

0.95–1.02

0.45

PIM-3 score

1.04

1.03–1.06

<0.001

Comorbid conditions
None

Reference

1 comorbid condition

1.11

0.62–2.01

0.72

≥2 comorbid conditions

1.78

1.07–2.99

0.03

0.63

0.37–1.06

0.08

fluid, and laboratory derangements beyond arbitrary cutpoints (e.g., international normalized ratio >2), should not
preclude the clinical diagnosis of severe sepsis and/or septic shock. A refined consensus definition that more closely
matches the clinical definition and establishes a spectrum
of risk concordant with outcome, similar to that of the recent at-risk, mild, moderate, and severe pediatric ARDS
definitions [32], would benefit both research scientists and
clinicians.
By quantifying the extent to which physician diagnosis
and consensus criteria overlap, one can better understand the potential loss of efficacy as research findings
are adopted at the bedside. Previous studies show that
efficacious therapies in clinical trials are often extended
to a broader patient population, with a more variable
and perhaps even a distinct pathophysiology [14–17]. To
our knowledge, this is the first multicenter, international
study of the generalizability of consensus criteria for
pediatric severe sepsis. Because only 69 % of patients
with a physician’s diagnosis of severe sepsis met consensus criteria, it may not be appropriate to apply the results of a clinical trial to up to one-third of children
treated for severe sepsis in a general PICU practice. Although a potential decrement from efficacy to effectiveness
may not dissuade widespread implementation of a new
therapy, enthusiasm could be altered if concerns over adverse effects, resource utilization, or costs were taken into
consideration.
It is also noteworthy that nearly half of patients in the
SPROUT study were identified as having severe sepsis by
consensus criteria without corroboration by physician
diagnosis. This likely reflects that both physician diagnosis and consensus criteria rely on relatively non-specific

Weiss et al. Critical Care (2015) 19:325

changes in physiology that are commonly found in critically ill children in general, not just in children with
sepsis. Still, this observation highlights an opportunity to
refine future iterations of consensus criteria and address
variability in physician diagnosis to identify sepsis. Patients with preexisting neuromuscular disorders, such as
cerebral palsy and epilepsy, were particularly likely to
meet consensus criteria for severe sepsis despite an alternative clinical diagnosis. Many of these patients have
dysautonomia or altered physiologic responses to illness
that make it challenging to apply predefined rigid criteria. The higher rate of unknown primary site of infection suggests that consensus criteria may be less specific
than physician diagnosis in identifying patients with a
true infection. It is also possible that consensus criteria
include PICU patients with a high severity of illness,
namely those with shock and multiorgan system dysfunction caused by non-septic insults, who are commonly treated empirically for infection even if clinical
suspicion is low. Alternatively, if physician diagnosis
does not corroborate consensus criteria despite true
presence of severe sepsis, there may be a higher rate of
parental or clinician refusal to participate in research
because the clinicians managing the patient may not
agree on the diagnosis of concern. The incorporation
of new biomarkers or novel microbiologic detection
systems that improve early sensitivity and specificity
for invasive infections into future revisions of the consensus criteria may improve alignment with physician
diagnosis.
There are several limitations to this study. First, physician diagnosis and the application of consensus criteria
to identify patients with severe sepsis could not be independently verified. The reasons why patients were not
identified as having severe sepsis by one or both definitions were also not available. Although these concerns
may have led to misclassification of some patients, it is
unlikely that such a bias would have preferentially affected one group. Moreover, because we included only
physicians practicing in a PICU setting, 89 % of whom
were trained in pediatric critical care medicine, the level
of agreement for other providers who commonly treat
sepsis (e.g., emergency physicians) may differ from our
results. A second limitation is that criteria used for physician diagnosis were not standardized. Although this
may have increased variability in physician diagnosis
across providers and sites, such an approach reflects that
physicians often differ in their diagnostic approach.
Third, the higher proportion of patients with available
laboratory measures in the consensus criteria only and
both definition groups may itself have increased the likelihood of identification by consensus criteria because, in
the absence of available data, these measures were assumed to be within normal limits. Although it is more
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likely that sicker patients had directed laboratory testing
performed than unsuspected organ dysfunction was discovered through routine laboratory testing, differential
availability of laboratory results may have been a source
of misclassification bias. Finally, because a “gold standard” does not exist, it is not possible to determine the
degree to which either definition correctly identified
pediatric patients with severe sepsis or compared the
sensitivity and specificity of the two definitions.

Conclusions
Physician diagnosis of pediatric severe sepsis achieved
only a moderate level of agreement with consensus criteria across this multicenter, international point prevalence study. The results of a research study based on
current consensus criteria may not be generalizable to
nearly one-third of pediatric patients diagnosed with severe sepsis in a PICU. Further research is needed to
understand the extent to which the specificity of consensus criteria and variability in physician diagnosis may be
contributing to this discordant identification of pediatric
severe sepsis. Attempts to better align consensus definitions with clinical diagnosis by establishing a continuous
spectrum of illness severity are needed.
Key messages
 Although consensus criteria for pediatric sepsis were









established to facilitate consistent enrollment across
research studies, the extent to which these criteria
reflect physician diagnosis of severe sepsis, which
underlies external validity for pediatric sepsis
research, is not known.
Of 6925 PICU patients screened at 128 PICUs in 26
countries, 706 patients were identified by physician
diagnosis and/or consensus criteria as having severe
sepsis.
Only 301 patients (42.6 %) were identified by both
physician diagnosis and consensus criteria
(κ 0.57 ± 0.02).
The 31 % of patients with physician-diagnosed
severe sepsis who did not meet consensus criteria
were younger, had a lower severity of illness, and a
lower PICU mortality than those who met
consensus criteria or both definitions.
The results of a research study based on consensus
criteria may have limited generalizability to nearly
one-third of PICU patients diagnosed with severe
sepsis.
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